Ehrlichia Chaffeensis Antibody (IgG) Test

If you have ever pulled a tick off your skin, spent summers in the woods of the southeastern or south-central United States, or come down with an unexplained fever and headache after outdoor work, this test answers a specific question: has your immune system met Ehrlichia chaffeensis, the bacterium behind human monocytic ehrlichiosis?

The infection is easy to miss. It looks like flu at first, then can progress to dangerously low platelets, organ failure, and, in immunocompromised people, death. Finding the fingerprint of prior exposure can explain old mystery illnesses, guide treatment of a current one, and clarify what you are dealing with when a tick-borne disease is on the differential.

What This Test Is Actually Measuring

IgG (immunoglobulin G) is the long-lived class of antibody your body makes after it meets a new pathogen. When this test comes back positive, it means your B cells (the immune cells that produce antibodies) have at some point recognized E. chaffeensis and built a targeted response.

A positive IgG does not automatically mean you are sick right now. Many seropositive people in endemic regions feel fine and have no memory of being ill. Among Latino food processing workers and their families in North Carolina, 19.9% tested positive. Among farm workers and indigenous people in Peninsular Malaysia, positivity rates reached 29.9% and 34.3%.

In other words, in places where lone star ticks live, silent past infection is common. The IgG test reflects that history, not only active disease.

Human Monocytic Ehrlichiosis, the Disease This Signals

E. chaffeensis causes human monocytic ehrlichiosis (HME), a tick-borne illness transmitted mainly by lone star ticks. The bacterium hides inside white blood cells called monocytes. Classic symptoms include fever, headache, muscle aches, and low platelets (thrombocytopenia), often with elevated liver enzymes. Severe cases can progress to respiratory failure, disseminated intravascular coagulation (a life-threatening clotting breakdown), encephalitis, and endocarditis.

In people with HIV, cancer treatment, or organ transplants, HME can be more severe and more likely to be fatal. Recognition of the infection with serology and prompt doxycycline treatment has been shown to reverse multi-organ failure in case series.

Who Should Consider Testing

IgG testing is most useful when there is a clinical reason to ask. Published research supports testing in these groups.

• Unexplained fever after tick exposure: fever, headache, muscle pain, and low platelets in someone who has spent time in endemic areas are the classic picture.
• Immunocompromised adults in endemic regions: HIV-positive, transplant, and immunosuppressed patients have worse outcomes and benefit from aggressive workup.
• Retrospective confirmation: if you had a tick-borne-looking illness weeks or months ago that was never diagnosed, a paired or late IgG can confirm what happened.
• Household clusters: in the North Carolina food worker study, having a seropositive household member was a major risk factor for being seropositive yourself.

Reference Ranges and What a Titer Means

These cutoffs come from CDC surveillance criteria and indirect immunofluorescence assay (IFA) practice used in published serologic studies. Titers are reported as dilutions (1:64 means the antibody signal is still detectable after diluting your serum 64-fold). Your lab may use slightly different cutpoints or an ELISA instead of IFA, so the specific numbers can shift.

Compare your results within the same lab over time for the most meaningful trend. Different antigen preparations can produce titer differences of up to fourfold even on the same blood sample.

Why Early Testing Can Fool You

IgG takes time to show up. In a series of patients with culture-confirmed E. chaffeensis infection, only a minority had diagnostic antibody titers when they first presented, even though all were PCR-positive at that moment. Most eventually seroconverted as the immune response matured.

This is why a single negative IgG in a sick person does not rule out ehrlichiosis, and why clinicians who suspect acute disease often order PCR on blood at the same time. PCR detects the bacterium's DNA directly, which is available before your antibody response catches up.

Cross-Reactivity and the Limits of a Single Positive

A single positive IgG is useful, but not definitive. Antibodies to E. chaffeensis frequently cross-react with related organisms, including Ehrlichia ewingii, Ehrlichia canis, and Anaplasma phagocytophilum. Heat shock proteins can also drive cross-reactivity with Borrelia burgdorferi (the Lyme bacterium).

That means a positive E. chaffeensis IgG may reflect exposure to a cousin organism rather than this specific species. In clinical settings where multiple tick-borne pathogens circulate, panels that test for Anaplasma, Borrelia, and Bartonella are typically ordered together, and co-positivity is common.

Tracking Your Trend

For this biomarker, serial tracking is not about monitoring a chronic number the way you would with cholesterol. It is about comparing an acute and convalescent sample to capture a fourfold rise in titer, which is the strongest serologic evidence that an infection happened recently.

If you test during an acute illness and the IgG is negative or low, retest in 2 to 4 weeks. In culture-confirmed series, seroconversion has been observed within weeks of symptom onset. In a study of a related pathogen (human granulocytic ehrlichiosis), antibodies peaked in the first month and remained detectable in about half of patients a year later, which is why a single high titer alone cannot date an infection.

For epidemiologic or exposure screening in healthy people, a baseline result is informative, and repeat testing makes sense mainly if you have a new tick-borne-looking illness or a known high-risk exposure.

What to Do If Your Result Is Positive

A positive IgG by itself, without symptoms, does not require antibiotic treatment. The decision path depends on what else is happening.

• Sick right now with compatible symptoms: ask for Ehrlichia PCR on blood and a complete blood count with differential to look for low platelets and low white cells. Doxycycline is the recommended treatment and works best when started early, before labs confirm anything.
• Asymptomatic and positive: repeat testing in 2 to 4 weeks to see whether the titer is rising (active infection) or stable (past exposure). A stable titer in a well person usually means a historic, resolved infection.
• Unexpectedly very high titer without clear exposure: consider autoimmune disease, especially systemic lupus, which has produced false-positive Ehrlichia antibodies in published case reports. An ANA (antinuclear antibody) screen can help clarify the picture.
• Positive for more than one tick-borne pathogen: involve an infectious disease specialist. Cross-reactivity and true coinfection both happen, and distinguishing them affects treatment.

When Results Can Be Misleading

A few factors can produce a number that does not reflect your true infection status.

• Testing too early: during the first days of acute illness, IgG is often still negative. Pair with PCR and plan a follow-up sample.
• Active autoimmune disease: systemic lupus erythematosus (SLE) can drive false-positive Ehrlichia IgG and IgM titers. Published case reports describe titers normalizing once immunosuppressive therapy controls the autoimmune disease.
• Cross-reacting antibodies: prior exposure to Ehrlichia ewingii, E. canis, Anaplasma phagocytophilum, or, through heat shock protein cross-reactivity, Borrelia burgdorferi can produce a positive E. chaffeensis IgG.
• Lab-to-lab variation: IFA titers can differ up to fourfold between antigen preparations and laboratories. Trend within the same lab where possible.